Background Monoclonal antibodies (mAbs) are laboratory‐produced molecules derived
from the B cells of an infected host. They are being investigated as a potential therapy for …

Objective To evaluate the efficacy and safety of antiviral antibody therapies and blood
products for the treatment of novel coronavirus disease 2019 (covid-19). Design Living …

Background There are many pharmacologic therapies that are being used or considered for
treatment of coronavirus disease 2019 (COVID-19). There is a need for frequently updated …

Abstract Casirivimab/imdevimab (Ronapreve™; REGEN-COV™) is a co-packaged
combination of two neutralizing immunoglobulin gamma 1 (IgG1) human monoclonal …

Background Monoclonal antibodies (mAbs) are laboratory‐produced molecules derived
from the B cells of an infected host. They are being investigated as potential prophylaxis to …

Background Antibody-based strategies for COVID-19 have shown promise in prevention
and treatment of early disease. COVID-19 convalescent plasma (CCP) has been widely …

Multiple variants of SARS-CoV-2 have emerged and are now prevalent at the global level.
Currently designated variants of concern (VOCs) are B. 1.1. 7, B1. 351, P. 1, B. 1.617. 2 …

Aim Several randomized trials have evaluated the effect of neutralizing monoclonal
antibodies on the risk of hospital admission and risk of mortality in patients with COVID-19 …

Objectives To assess the effects of interventions authorised by the European Medicines
Agency (EMA) or the US Food and Drug Administration (FDA) for prevention of COVID-19 …

Background The coronavirus disease 2019 (COVID‐19) has spread worldwide since early
2020, and there are still no signs of resolution. The Japanese Clinical Practice Guidelines …